Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder

Vyant Bio, Inc. and Cyclica, Inc. announced a non-exclusive strategic collaboration combining Vyant Bio’s patient-derived complex organoid biology alongside Cyclica’s proteome-wide, Artificial Intelligence enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder, a severe neurodevelopmental epilepsy disorder with no effective treatments or cure.